- Home
- FOXX vs QNCX Comparison
FOXX vs QNCX Comparison
Compare FOXX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | QNCX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 17.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FOXX | QNCX |
|---|---|---|
| Price | $2.50 | $31.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 19.6K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $0.08 |
| 52 Week High | $7.90 | $35.41 |
Technical Indicators
Market Signals| Indicator | FOXX | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 58.65 |
| Support Level | $2.26 | $29.95 |
| Resistance Level | $4.90 | $35.38 |
| Average True Range (ATR) | 0.28 | 2.11 |
| MACD | -0.02 | -0.80 |
| Stochastic Oscillator | 12.15 | 35.81 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.